TY - JOUR
T1 - Zofenopril and Ramipril in Combination with Acetyl Salicylic Acid in Postmyocardial Infarction Patients with Left Ventricular Systolic Dysfunction
T2 - A Retrospective Analysis of the SMILE-4 Randomized, Double-Blind Study in Diabetic Patients
AU - Borghi, Claudio
AU - Omboni, S.
AU - Novo, Salvatore
AU - Vinereanu, Dragos
AU - Ambrosio, G. A.
AU - Ambrosioni, Ettore
AU - Dimitrios, Alexopolulus
AU - Ioannis, Nanas
AU - Marco, Agrusta
AU - Antonio, Barsotti
AU - Serena, Bergerone
AU - Luigi, Caliendo
AU - Pio, Caso
AU - Antonio, Castello
AU - Cianflone, Domenico
AU - Tommaso, Cipolla
AU - De Ferrari, Gaetano
AU - Giuseppe, De Nittis
AU - Livio, Dei Cas
AU - Paolo, Di Pasquale
AU - Rosario, Evola
AU - Luciano, Fattore
AU - Raffaele, Ferrante
AU - Antonio, Fiscella
AU - Achille, Gaspardone
AU - Giuseppe, Ielasi
AU - Niccoló, Marchionni
AU - Giancarlo, Marenzi
AU - Filippo, Marte
AU - Federico, Miccoli
AU - Patrizia, Noussan
AU - Mario, Orlandi
AU - Giancarlo, Piovaccari
AU - Maurizio, Porcu
AU - Presbitero, Patrizia
AU - Antonio, Raviele
AU - Emiliano, Renaldini
AU - Jorge, Salerno Uriarte
AU - Giovanni, Storti
AU - Corrado, Tamburino
AU - Pierfranco, Terrosu
AU - Roberto, Testa
AU - Rita, Trinchero
AU - Bernardino, Tuccillo
AU - Ludovico, Vasquez
AU - Quinto, Villani Giovanni
AU - Garcia, Alvés Mario
AU - Aurora, Andrade
AU - Silva, Cardoso
AU - Ilidio, Moreira Joseà
AU - Catalina, Arsenescu Georgescu
AU - Mircea, Cinteza
AU - Maria, Dorobantu
AU - Dominic, Ionescu
AU - Ioan, Manitiu
AU - Florin, Ortan
AU - Calin, Pop
AU - Mariana, Radoi
AU - Yuriy, Alexandrovich Vasyuk
AU - Victor, Avenirovitch Kostenko
AU - Yuriy, Borisovich Karpov
AU - Vira, Iosifovna Tseluiko
AU - Abram, Lvovich Syrkin
AU - Boris, Mikhailovich Goloschekin
AU - Evgeniy, Mikhaylovich Nifontov
AU - Sergey, Nikolaevich Tereschenko
AU - Natalia, Nikolaevna Burova
AU - Konstantin, Nikolayevich Zrazhevsky
AU - Grigory, Pavlovich Arutuynov
AU - Valentin, Sergeevich Moiseev
AU - Leonid, Victorovich Rudenko
AU - Alexander, Yurievich Vishnevsky
AU - Diaz, D. L Y De La Yera
AU - Fernández, Romero
AU - Cevat, Kirma
AU - Kayikcioglu, Meral
AU - Abdurrahman, Oğuzhan
AU - Dilek, Ural Komsuoglu
AU - Olena, Ankindinovna Koval
AU - Alexan, Nikolaevich Parkhomenko
AU - Igor, Petrovich Vakalyuk
AU - Mykola, Tihonovich Vatutin
AU - Valerii, Vladimirovich Batushkin
PY - 2016/4/1
Y1 - 2016/4/1
N2 - Objective: In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods: The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results: A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as diabetics. The adjusted rate of MACE was lower under zofenopril than under ramipril in both nondiabetics [27.9% vs. 34.9% ramipril; odds ratio, OR and 95% confidence interval: 0.55 (0.35, 0.86)] and diabetics [30.9% vs. 41.3%; 0.56 (0.18, 1.73)], although the difference was statistically significant only for the nondiabetic group (P = 0.013). Zofenopril was superior to ramipril as regards to the primary study endpoint in the subgroup of 157 patients with uncontrolled blood glucose (≥126 mg/dL), regardless of a previous diagnosis of diabetes [0.31 (0.10, 0.90), P = 0.030]. Zofenopril significantly reduced the risk of hospitalization for cardiovascular causes in both nondiabetics [0.64 (0.43, 0.96), P = 0.030] and diabetics [0.38 (0.15, 0.95), P = 0.038], whereas it was not better than ramipril in terms of prevention of cardiovascular deaths. Conclusions: This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril plus ASA in the prevention of long-term MACE also in the subgroup of patients with diabetes mellitus.
AB - Objective: In the SMILE-4 study, zofenopril + acetyl salicylic acid (ASA) was more effective than ramipril + ASA on 1-year prevention of major cardiovascular events (MACE) in patients with acute myocardial infarction complicated by left ventricular dysfunction. In this retrospective analysis, we evaluated drug efficacy in subgroups of patients, according to a history of diabetes mellitus. Methods: The primary study endpoint was 1-year combined occurrence of death or hospitalization for cardiovascular causes. Diabetes was defined according to medical history (previous known diagnosis). Results: A total of 562 of 693 (81.0%) patients were classified as nondiabetics and 131 (18.9%) as diabetics. The adjusted rate of MACE was lower under zofenopril than under ramipril in both nondiabetics [27.9% vs. 34.9% ramipril; odds ratio, OR and 95% confidence interval: 0.55 (0.35, 0.86)] and diabetics [30.9% vs. 41.3%; 0.56 (0.18, 1.73)], although the difference was statistically significant only for the nondiabetic group (P = 0.013). Zofenopril was superior to ramipril as regards to the primary study endpoint in the subgroup of 157 patients with uncontrolled blood glucose (≥126 mg/dL), regardless of a previous diagnosis of diabetes [0.31 (0.10, 0.90), P = 0.030]. Zofenopril significantly reduced the risk of hospitalization for cardiovascular causes in both nondiabetics [0.64 (0.43, 0.96), P = 0.030] and diabetics [0.38 (0.15, 0.95), P = 0.038], whereas it was not better than ramipril in terms of prevention of cardiovascular deaths. Conclusions: This retrospective analysis of the SMILE-4 study confirmed the good efficacy of zofenopril plus ASA in the prevention of long-term MACE also in the subgroup of patients with diabetes mellitus.
KW - Acetyl salicylic acid
KW - Acute myocardial infarction
KW - Angiotensin-converting enzyme inhibitors
KW - Diabetes mellitus
KW - Left ventricular dysfunction
KW - Ramipril
KW - Zofenopril
UR - http://www.scopus.com/inward/record.url?scp=84959269546&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84959269546&partnerID=8YFLogxK
U2 - 10.1111/1755-5922.12175
DO - 10.1111/1755-5922.12175
M3 - Article
SN - 1755-5914
VL - 34
SP - 76
EP - 84
JO - Cardiovascular Therapeutics
JF - Cardiovascular Therapeutics
IS - 2
ER -